Celgene Co. (NASDAQ:CELG) Director Gilla Kaplan sold 9,250 shares of Celgene stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $94.83, for a total value of $877,177.50. Following the completion of the transaction, the director now directly owns 94,801 shares in the company, valued at $8,989,978.83. The transaction was disclosed in a legal filing with the SEC, which is available through this link.
Gilla Kaplan also recently made the following trade(s):
- On Thursday, February 15th, Gilla Kaplan sold 9,250 shares of Celgene stock. The shares were sold at an average price of $95.99, for a total value of $887,907.50.
Shares of Celgene Co. (CELG) opened at $93.89 on Thursday. The company has a current ratio of 4.99, a quick ratio of 4.80 and a debt-to-equity ratio of 2.29. Celgene Co. has a twelve month low of $88.32 and a twelve month high of $147.17. The stock has a market capitalization of $70,591.68, a P/E ratio of 13.68, a price-to-earnings-growth ratio of 0.66 and a beta of 1.49.
Celgene (NASDAQ:CELG) last posted its quarterly earnings data on Thursday, January 25th. The biopharmaceutical company reported $1.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.78 by $0.09. Celgene had a return on equity of 67.50% and a net margin of 22.38%. The company had revenue of $3.48 billion for the quarter, compared to the consensus estimate of $3.46 billion. During the same period in the previous year, the business earned $1.61 EPS. Celgene’s revenue for the quarter was up 16.9% compared to the same quarter last year. equities analysts anticipate that Celgene Co. will post 7.68 earnings per share for the current fiscal year.
Celgene announced that its board has initiated a stock repurchase program on Wednesday, February 14th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the biopharmaceutical company to repurchase shares of its stock through open market purchases. Stock buyback programs are generally a sign that the company’s leadership believes its shares are undervalued.
Hedge funds have recently bought and sold shares of the business. Thompson Davis & CO. Inc. increased its holdings in Celgene by 5.9% during the 2nd quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock worth $100,000 after purchasing an additional 43 shares during the last quarter. Virtue Capital Management LLC bought a new stake in shares of Celgene in the 4th quarter valued at approximately $101,000. Arcadia Investment Management Corp MI increased its holdings in shares of Celgene by 118.7% in the 3rd quarter. Arcadia Investment Management Corp MI now owns 737 shares of the biopharmaceutical company’s stock valued at $107,000 after acquiring an additional 400 shares during the last quarter. Robecosam AG bought a new stake in shares of Celgene in the 3rd quarter valued at approximately $114,000. Finally, Guidant Wealth Advisors bought a new stake in shares of Celgene in the 3rd quarter valued at approximately $119,000. Institutional investors own 77.84% of the company’s stock.
Several equities analysts have recently weighed in on CELG shares. BMO Capital Markets lifted their price objective on Celgene from $148.00 to $155.00 and gave the company an “outperform” rating in a research note on Friday, November 17th. Cantor Fitzgerald set a $112.00 price objective on Celgene and gave the company a “hold” rating in a research note on Wednesday, January 17th. Morgan Stanley raised Celgene from an “underweight” rating to an “equal weight” rating in a research note on Friday, October 27th. Cann reaffirmed a “buy” rating on shares of Celgene in a research note on Thursday, October 26th. Finally, Citigroup reduced their price objective on Celgene from $140.00 to $102.00 and set a “neutral” rating on the stock in a research note on Friday, October 27th. Two equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, eighteen have given a buy rating and two have given a strong buy rating to the company. Celgene presently has an average rating of “Buy” and a consensus target price of $130.25.
TRADEMARK VIOLATION WARNING: This piece of content was originally posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this piece of content on another website, it was copied illegally and republished in violation of international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.thelincolnianonline.com/2018/02/22/celgene-co-celg-director-sells-877177-50-in-stock.html.
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.